Paige

Axia Public Relations adds bilingual employee

Retrieved on: 
Thursday, September 7, 2023
Morgan Stanley, Bachelor of Science in Public Health, Comcast, Communication, University, PGA Tour, Paige, Associate, University of North Florida, PR, Management

JACKSONVILLE, Fla., Sept. 7, 2023 /PRNewswire/ -- Madison Paige is joining Axia Public Relations as a public relations assistant.

Key Points: 
  • JACKSONVILLE, Fla., Sept. 7, 2023 /PRNewswire/ -- Madison Paige is joining Axia Public Relations as a public relations assistant.
  • To address the needs of more than 52 million Spanish-language speakers, Axia sought to recruit Paige as a bilingual Spanish speaker.
  • "We are excited to have Madison Paige join the Axia team," Axia CEO Jason Mudd said.
  • At the University of Florida, Paige was an account executive for Alpha PR , a student-run public relations firm.

Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps Down

Retrieved on: 
Thursday, June 1, 2023
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Sandia National Laboratories, Partnership, APHIS, Therapy, Chairperson, Food microbiology, Biopharmaceutical, Consultant, Education minister, Stefanelli, BioMed Central, Personalized medicine, Diagnosis, Life Technologies, Human, Research, Kansas State University, Genomics, Paige, Science, USDA, Pathology, Roche, Medicine, Artificial intelligence, NYSE, Independent Board for Presbyterian Foreign Missions, Microbiology, Automation, Fine chemical, Management, Molecular medicine

Separately, Alexander L. Cappello has stepped down from the Company’s Board.

Key Points: 
  • Separately, Alexander L. Cappello has stepped down from the Company’s Board.
  • Jill Bieker Stefanelli, Ph.D. joins Navidea’s Board of Directors with demonstrated experience leading fast-paced organizations focused on transformative precision medicine.
  • Separately, Alexander L. Cappello, after having joined Navidea in 2021 and recently serving as Chair of the Board, has decided to step down to pursue opportunities outside the organization.
  • “We thank Mr. Cappello for his contribution,” said John K. Scott, Jr, Navidea’s Vice Chair of the Board.

Clutch Global Top B2B Leader Awards 2022: Paige Logistics Was Officially Honoured Among The Top Global B2B And Canadian Leader In Shipping, Rail, And Flatbed Trucking

Retrieved on: 
Tuesday, December 20, 2022
Research, B2B, Transport, Paige, RFP, Service, Marketing, Cargo, Rail freight transport, Clutch

Alexander Crane, President and CEO of Paige Logistics, has said about the award, “it’s been an honour to make 2022 Clutch’s global rankings.

Key Points: 
  • Alexander Crane, President and CEO of Paige Logistics, has said about the award, “it’s been an honour to make 2022 Clutch’s global rankings.
  • Clutch meticulously considers the finest of the best before holding awards each year, this award has brought a lot to us at Paige Logistics.
  • Some of Paige Logistics’ recognized services include:
    Logistics – You will always receive the most efficient carrier to meet your precise timelines.
  • Ready to work with you to provide industry-specific bespoke solutions, the logistics managers at Paige Logistics are transportation professionals.

Righting Real Estate Business Planning Clinic 2023 Helps Realtors De-Stress Through Successful Planning

Retrieved on: 
Friday, December 23, 2022
Fortnight, Selling Sunset, Organizer, Real, Small business, Knowledge, Life, Venmo, Real estate agent, Business, Failure, Attention, Nut, Personality, Mental health, Carpool, Real estate, Paige, Housing, Property management, Management

NEW ORLEANS, Dec. 23, 2022 /PRNewswire-PRWeb/ -- After nearly two decades, Courtney Kattengell, owner of Righting Real Estate, is convinced that real estate is the most exciting field. She says the industry hurls fresh challenges and opportunities daily, and she loves making order out of the chaos. After witnessing the recent alarming burnout among realtors, she began providing one-on-one coaching, retreats, workshops, and other services to realtors.

Key Points: 
  • Her Realtor's Business Planning Clinic 2023, scheduled for Friday, January 20, 2023, from 10 am to 11:30 am, offers an online opportunity for Realtors to dive into their business model, improve its efficiency, and grow with success.
  • NEW ORLEANS, Dec. 23, 2022 /PRNewswire-PRWeb/ -- After nearly two decades, Courtney Kattengell, owner of Righting Real Estate, is convinced that real estate is the most exciting field.
  • The Realtor's Business Planning Clinic 2023, scheduled for Friday, January 20, 2023, from 10 am to 11:30 am via zoom , will offer an online opportunity for Realtors to dive into their business model, improve its efficiency and grow with success.
  • From mission statements to budgets and everything in between, the Business Planning Clinic seeks to help Realtors succeed in 2023 with a business plan template!

Ultivue Announces Co-Marketing and Co-Development Collaboration with Paige for AI-Powered Biomarker Imaging Solutions for Precision Medicine

Retrieved on: 
Thursday, April 7, 2022
Data Management, Health, Technology, Other Health, Software, General Health, Biotechnology, Adoption, MIF, LinkedIn, Data management, MSK, Patient, Tumor microenvironment, Research, Pathology, Memorial Sloan Kettering Cancer Center, Precision medicine, CEO, Marie Cassidy, Paige, Industry, Technology, Review, Twitter, Goal, Oncology, Workflow, Solution, FDA, AI, Deep learning, Partnership, Medical device, Medical imaging

The fast, zero-footprint, scanner-agnostic viewer, storage capabilities and AI-based diagnostic software help pathologists review cases and support their overall workflow.

Key Points: 
  • The fast, zero-footprint, scanner-agnostic viewer, storage capabilities and AI-based diagnostic software help pathologists review cases and support their overall workflow.
  • Ultivue, a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation, develops unique platform agnostic solutions for use in both mIF imaging and spatial phenomics.
  • By uniting two platform-agnostic technologies, we are well-positioned to enable broad adoption of our AI-powered biomarker imaging solutions.
  • Ultivue provides researchers in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology.

Paige and Flagship Biosciences Announce Partnership to Expand Access to Immuno-Oncology Biomarker Analysis Tools

Retrieved on: 
Thursday, February 17, 2022
Software, Research, General Health, Pharmaceutical, Data Management, Oncology, Technology, Clinical Trials, Science, Biotechnology, FDA, Health, Other Science, Memorial Sloan Kettering Cancer Center, MSK, Adoption, Patient, AI, CEO, Immunohistochemistry, Immunotherapy, PD-L1, Tumor microenvironment, Macrophage, Technology, TME, LinkedIn, TILS, Twitter, FDA, Marie Cassidy, View, CLIA, Partnership, Pathology, Workflow, IHC, Multimedia, Â, Industry, Drug development, Oncology, Medical device, Medical imaging, Paige, Flagship Biosciences, PAIGE, FLAGSHIP BIOSCIENCES

By enabling pathologists to access Flagships PD-L1 analysis tool directly within the Paige Platform, we are providing pathologists and oncologists quicker access to biomarker testing results that will inform treatment planning, said Andy Moye, Ph.D., CEO at Paige.

Key Points: 
  • By enabling pathologists to access Flagships PD-L1 analysis tool directly within the Paige Platform, we are providing pathologists and oncologists quicker access to biomarker testing results that will inform treatment planning, said Andy Moye, Ph.D., CEO at Paige.
  • This partnership can make it easier and more efficient for pathologists to quantify a prominent immunotherapy biomarker and can help improve patient care.
  • TissueInsights integration with Paiges platform will truly provide a diagnostic service unmatched in the industry, said Trevor Johnson, CEO at Flagship Biosciences.
  • Founded in 2009 and headquartered in Broomfield, Colorado, Flagship Biosciences, Inc. is a technology-driven tissue analysis services company delivering the most accurate and informative data available.

Agendia to Provide First Digital MammaPrint Capability to Brazil

Retrieved on: 
Wednesday, January 12, 2022
Oncology, Health, General Health, Radiology, Clinical Trials, Pharmaceutical, Biotechnology, Mortality, Marie Cassidy, Patient, Surgeon, Biology, Breast cancer, DOI, Genomics, Paige, Population, Science, Partnership, Oncology, Digital, Disease, Recurrence, Prognosis, Digital technology, Artificial intelligence, AI, Pathology, Cancer, Risk, Neoplasm, Behavior, Physician, Woman, Medical imaging, MammaPrint

Brazil is the first country to have samples analyzed by Digital MammaPrint, allowing physicians and their patients to benefit from genomic insights derived from a digitized image of a breast cancer tumor.

Key Points: 
  • Brazil is the first country to have samples analyzed by Digital MammaPrint, allowing physicians and their patients to benefit from genomic insights derived from a digitized image of a breast cancer tumor.
  • Agendias Digital MammaPrint is powered by the cloud-based Paige Platform , a partnership that the two companies announced in November 2020 .
  • Introducing Digital MammaPrint to physicians and their patients in Brazil marks an important step in increasing access to quality, AI-enabled diagnostic tests, said David Klimstra, M.D., Founder and Chief Medical Officer at Paige.
  • Together, MammaPrint and BluePrint provide a holistic view of an individual patients breast cancer, enabling physicians to objectively select the best treatment plan.

Paige Founder and Cancer Pathology Thought Leader Dr. David Klimstra Featured on the Impact Podcast with John Shegerian

Retrieved on: 
Tuesday, December 7, 2021
Other Education, Research, Continuing, Education, Hardware, Other Consumer, Data Management, Women, Science, Seniors, Technology, Other Professional Services, Men, Health, Human Resources, Family, Consumer, Training, Professional Services, Other Communications, Environment, Other Manufacturing, Communications, Manufacturing, Other Health, Blogging, Other Science, Other Technology, Linda, Johnson & Johnson, NBA, Electronics, Pathology, Dell, Lipton, Procter & Gamble, Research, Goodyear Tire and Rubber Company, ERI, Virginity, GE, Pancreas, General Motors, ESPN, Technology, Beyond Meat, Comerica, Seventh generation, Google Podcasts, Cornell University, Ellen, PTSD, The Hershey Company, Human, Medical laboratory, Nestlé Waters, Tennis, Liver, Yale University, Cancer, Memorial Sloan Kettering Cancer Center, Paige, Gastrointestinal tract, MacArthur Foundation, Intel, Spain, Molson Coors Beverage Company, Panasonic, FedEx, Consultant (medicine), Patrón, Best Buy, JetBlue, FDA, Waste management, Neoplasm, Weill Cornell Medicine, IBM, AI, Amazon Music, Medical imaging, Music

David Klimstra MD, Founder and Chief Medical Officer at Paige , the first company to receive FDA approval for an AI product in digital pathology, Paige Prostate, is a featured guest on the Impact Podcast with John Shegerian this week.

Key Points: 
  • David Klimstra MD, Founder and Chief Medical Officer at Paige , the first company to receive FDA approval for an AI product in digital pathology, Paige Prostate, is a featured guest on the Impact Podcast with John Shegerian this week.
  • Dr. Klimstra also serves as Medical Consultant at Memorial Sloan Kettering Cancer Center and Professor of Pathology and Laboratory Medicine at Weill Medical College of Cornell University.
  • and completed a residency in anatomic pathology at Yale University, and he completed fellowship training in oncologic surgical pathology at Memorial Sloan Kettering Cancer Center.
  • The Impact Podcast with John Shegerian is available for listening on ImpactPodcast.com , Apples iTunes , Amazon Music, Google Podcasts , Spotify , libsyn , and as part of iHeartRadios digital broadcast, reaching over 120 million users.

FDA Authorizes Software that Can Help Identify Prostate Cancer

Retrieved on: 
Tuesday, September 21, 2021
Office of Inspector General, U.S. Department of Health and Human Services, Prostate, Dietary supplement, Food, Korea Disease Control and Prevention Agency, Man, Animal, Review, Vaccine, Smokeless tobacco, Diagnosis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Software, Cancer, Multimedia, Cosmetics, FDA Center for Devices and Radiological Health, Biopsy, Prostate cancer, Public health, List of pathologists, Device, Center, Human services, Paige, Trial of the century, Intelligence, U.S. Department of Commerce Office of Security, China Biologic Products, De novo, Safety, Marie Cassidy, Classification, Medical imaging, Medical device

"Pathologists examine biopsies of tissue suspected for diseases, such as prostate cancer, every day.

Key Points: 
  • "Pathologists examine biopsies of tissue suspected for diseases, such as prostate cancer, every day.
  • "The authorization of this AI-based software can help increase the number of identified prostate biopsy samples with cancerous tissue, which can ultimately save lives."
  • Cancer that starts in the prostate is called prostate cancer.
  • According to the Centers for Disease Control and Prevention , aside from non-melanoma skin cancer, prostate cancer is the most common cancer among men in the United States.

Dr. David Klimstra joins Paige as Chief Medical Officer

Retrieved on: 
Thursday, June 3, 2021
Oncology, Medical devices, Health, Technology, Hospitals, Software, Given names, Pathology, Paige

Paige , the global leader in AI-based diagnostic software in pathology, today announced that leading pathologist and Paige co-founder David Klimstra, M.D.

Key Points: 
  • Paige , the global leader in AI-based diagnostic software in pathology, today announced that leading pathologist and Paige co-founder David Klimstra, M.D.
  • has joined as Chief Medical Officer effective August 2021.
  • We are thrilled to welcome Dr. Klimstra into his new role as we launch digital pathology products into clinics worldwide while ramping up development programs for new tissue types, said Leo Grady, Ph.D., Chief Executive Officer of Paige.
  • As Chair, Dr. Klimstra has led the evaluation and implementation of digital pathology workflows at MSK and built an academic computational pathology program.